BPD Research
Long/short equity

OncoMed's Cancer Stem Cell Therapies Could Provide Outsized Gains For Investors

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is an early developmental-stage biotechnology company focused on discovering and developing first-in-class monoclonal antibody ("MAB") therapeutics targeting cancer stem cells ("CSCs"). Based in Redwood City, California, OMED recently went public in July. The company sold 5,520,000 shares for $17.00 per share and received net cash proceeds of $82.7MM.

In normal tissue development, tissues are maintained over the long term by a small population of normal stem cells, which have self-renewal capabilities, or the ability to proliferate indefinitely while maintaining pluripotency. Similarly, it has been found that cancer cells can inappropriately activate self-renewal pathways, enabling a small set of cancer stem cells to exhibit properties similar to normal stem cells, but without the proper restraints.

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details